BAYRY Stock Recent News

CHICAGO--(BUSINESS WIRE)--Leading real-time supply chain visibility provider FourKites today announced that it will join Bayer and Graphic Packaging International in two separate tracks at the upcoming Gartner Supply Chain Symposium/Xpo™ 2024, where the world's chief supply chain officers (CSCOs), experts and supply chain leaders meet to share insights and strategies that can drive tangible impact in their organizations. FourKites founder and CEO Mathew Elenjickal will join Bayer's Global Direc.

Bayer's patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker.

A Missouri judge slashed a $1.56 billion verdict against Bayer to $611 million for three people who claimed its Roundup weed killer caused their cancer, by reducing punitive damages. Bayer said on Friday it is appealing.

M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.

Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.

Bayer on Thursday predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker's growth prospects after the failure of a promising anti-blood-clotting therapy.

Bayer's (BAYRY) pipeline candidate, elinzanetant, achieves primary and secondary goals in late-stage OASIS 3 study supporting submissions for marketing authorization.

Bayer said on Tuesday that it would request regulatory approval for its menopause drug after the daily pill was shown to ease hot flashes in a third late-stage trial, providing some relief for its pharmaceuticals unit that is reeling from a recent development setback.

Life sciences company Bayer (BAYRY, BAYN.DE) isn't breaking itself up right now.

Bayer CEO Bill Anderson joins 'Squawk on the Street' to discuss why the company hasn't broken up parts of the business, why the current strategy is the best way to go, and more.